摘要
目的探讨以克拉霉素为主的三联疗法治疗小儿幽门螺旋杆菌(HP)阳性消化性溃疡的临床效果。方法将68例患儿随机分成观察组与对照组,每组34例。两组均采取三联疗法,观察组给予克拉霉素+甲硝唑+奥美拉唑治疗,对照组给予阿莫西林+甲硝唑+奥美拉唑治疗,疗程均为5周。结果两组患儿溃疡愈合率比较无统计学差异(P>0.05),观察组HP清除率明显高于对照组(P<0.05),不良反应发生率则明显低于对照组(P<0.05)。结论以克拉霉素为主的三联疗法治疗小儿HP阳性消化性溃疡疗效肯定,在清除HP方面优于阿莫西林为主的三联疗法,且不良反应低,是较理想的方案。
Objective To discuss the clinical effect of the triple therapy of clarithromycin as the priority for treating children Helicobac-ter pylori （HP） positive peptic ulcer. Methods 68 children cases of HP positive peptic ulcer were randomly divided into the observa-tion group and control group, 34 cases in each group. The two groups adopted the triple therapy. The observation group was given clar-ithromycin plus metronidazole plus omeprazole treatment, while the control group was given amoxicillin plus metronidazole plus omepra-zole treatment. The course of treatmen was 5 weeks in the two groups. Results The ulcer healing rate had no statistical difference be-tween the two groupss（ P 〉 0. 05）, the HP clearance rate in the observation group was significantly higher than that in the control group （P 〈 0.05）, whereas the incidence rate of adverse reactions in the observation group was significantly lower than that in the control group （P 〈 0.05）. Conclusion The triple therapy predominated by clarithromycin has definite effect for treating children HP positive peptic ulcer, which is superior to the triple therapy of amoxicillin in the aspect of eliminating HP with low adverse reactions, and is the ideal treatment scheme of children HP positive peptic ulcer.
出处
《中国药业》
CAS
2013年第15期91-92,共2页
China Pharmaceuticals
